ViaNautis has taken 10,825 sq ft of space at Howard Group’s Unity Campus science and technology hub in Cambridge.
The nanomedicine company has signed a 10-year lease on the first floor laboratory, write-up and office space within the Cadence building at the campus.
Dr Fran Crawford, CEO of ViaNautis, said: “Moving to this state-of-the-art laboratory and associated offices is representative of ViaNautis’ growth trajectory. We are delighted to be expanding into these new premises which we hope will provide an inspiring workplace for our existing and future talent.”
Nicholas Bewes, CEO of Howard Group, added: “We warmly welcome ViaNautis to Unity Campus. The company’s commitment to advancing the field of gene therapy for the development of treatments for people with cystic fibrosis and CNS is admirable and we wish them every success in their pioneering work.”
Katherine Friend, director – investment and asset management at Howard Group, said: “The ViaNautis team will be joining an existing line up of exciting biomedical companies at Unity Campus, including Domainex, PhoreMost, Maxion Therapeutics, IONTAS, Sareum, Aqdot, Chimeris and Liminal BioSciences. I have no doubt that they will thrive in this dynamic environment and become an integral part of the entrepreneurial and collaborative campus community.”
Savills and JLL are joint agents at Unity Campus.
